Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

• Clearer transfusion guidelines could improve care for pre-term infants

  A report of Canadian neonatal units showed there is wide variation in transfusion practices for pre-term babies.

• Case report: Newborn with rare dual diagnosis of FNAIT and HDFN

  A newborn survived a rare combination of Jka hemolytic disease,HDFN and FNAIT thanks to early diagnosis and aggressive treatment.

• New surgical plan may help infants recover from brain fluid buildup

  Hydrocephalus from fetal and neonatal alloimmune thrombocytopenia (FNAIT) can be treated successfully with staged surgery, a review showed.

• Newborn with brain bleed and clot successfully treated with heparin

  In a recent case report, early use of heparin safely dissolved a life-threatening bleed and blood clot in the brain of a newborn.

• Pregnancies with blood disorders at greater risk of serious complications

  The study showed immune thrombocytopenia caused most maternal near-miss cases, especially when platelet counts dropped below 50×10⁹/L.

• Case report: Rare genetic mutation caused severe bleeding and FNAIT in infant

  A novel mutation, revealed by advanced genetic analysis, caused fetal and neonatal alloimmune thrombocytopenia (FNAIT) in a newborn.

• Potential FNAIT treatment approved for myasthenia gravis in US

  Nipocalimab’s success in gMG may bode well for its efficacy in treating FNAIT, a serious fetal condition with no approved therapies.

• Glanzmann’s thrombasthenia treatment may lead to increased FNAIT risk

  Nearly one in three babies born to mothers with Glanzmann’s thrombasthenia developed FNAIT in a recent study.

• Study: Infants exposed to preeclampsia more likely to need transfusions

  Very premature infants exposed to preeclampsia needed more platelet transfusions even though FNAIT was not observed in the sample.

• FNAIT avoided in pregnancy with Glanzmann’s thrombasthenia

  A recent case report highlighted how a well-planned approach can help prevent FNAIT in pregnancies at higher risk.